Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Overmoyer launched the Inflammatory Breast Cancer (IBC) Program at DF/BWCC in 2009, where she continues to serve as the principal investigator of many IBC research programs and clinical trials. She began her oncology career in 1989 at the University of Pennsylvania, where she trained in breast cancer and also participated in a major study in inflammatory breast cancer. She went on to develop the breast cancer program at the Cleveland Clinic and later developed two National Cancer Institute-sponsored studies on angiogenesis inhibitors and inflammatory breast cancer.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions